上海醫藥(02607.HK)治療潰瘍性結腸炎藥物獲批臨床試驗

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

上海醫藥(02607.HK)治療潰瘍性結腸炎藥物獲批臨床試驗

阿思達克 07-27 16:50

上海醫藥(02607.HK)公布，自主研發的I039獲得國家藥監局發出的臨床試驗批准通知書，將於近期啟動國內I期臨床試驗。該藥治療領域為消化道疾病，擬用適應症為潰瘍性結腸炎。

上海醫藥(02607.HK)

Relevant Stocks

上海醫藥(02607.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

上海醫藥(02607.HK)治療潰瘍性結腸炎藥物獲批臨床試驗

Services

About Us

Agreement Statement